Latest News

STAT Plus: Patient group asks BIO to denounce Catalyst over the $375,000 price of its rare disease drug




The controversy over a pricey rare-disease drug has ensnared the industry trade group for biotech companies, which is being challenged by a patent advocate to disavow “price gouging.”

In a letter to BIO chief executive Jim Greenwood, the Patients for Affordable Drugs wrote that the trade group has “an opportunity to disavow price gouging and exploitation of unrestrained market power” by Catalyst Pharmaceuticals, one of its members. The company has caused a furor over a drug with a $375,000 list price.

Continue to STAT Plus to read the full story…

Source link





Related posts

STAT Plus: Pharmalittle: Judges keep pharma secrets under wraps; Senate committees push drug pricing bills

Newsemia

Insights into DDT Resistance from the Drosophila melanogaster Genetic Reference Panel

Newsemia

Cobra Biologics to investigate continuous manufacturing of AAV for gene therapies

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy